{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:09:14Z","timestamp":1794884954966,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41416-019-0474-x","type":"journal-article","created":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T23:03:58Z","timestamp":1558307038000},"page":"1113-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial"],"prefix":"10.1038","volume":"120","author":[{"given":"Grainne M","family":"O\u2019Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bourdeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Leibowitz-Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Olney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Krzyzanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Reuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia L.","family":"Asa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez, M., Feng, L., Johnson, M. M., Ejaz, S., Habra, M. A., Rich, T. et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J. Clin. Endocrinol. Metab. 96, 717\u2013725 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/humu.21136","volume":"31","author":"CJ Ricketts","year":"2010","unstructured":"Ricketts, C. J., Forman, J. R., Rattenberry, E., Bradshaw, N., Lalloo, F., Izatt, L. et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum. Mutat. 31, 41\u201351 (2010).","journal-title":"Hum. Mutat."},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/his.13402","volume":"72","author":"J Turchini","year":"2018","unstructured":"Turchini, J., Cheung, V. K. Y., Tischler, A. S., De Krijger, R. R., Gill, A. J. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology 72, 97\u2013105 (2018).","journal-title":"Histopathology"},{"key":"474_CR4","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","volume":"23","author":"L Amar","year":"2005","unstructured":"Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O. et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 23, 8812\u20138818 (2005).","journal-title":"J. Clin. Oncol."},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein, L., Leshchiner, I., Walter, V., Danilova, L., Robertson, A. G., Johnson, A. R. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 31, 181\u2013193 (2017).","journal-title":"Cancer Cell."},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 7, 77\u201385 (2005).","journal-title":"Cancer Cell."},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","volume":"22","author":"WY Kim","year":"2004","unstructured":"Kim, W. Y., Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991\u20135004 (2004).","journal-title":"J. Clin. Oncol."},{"key":"474_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","volume":"23","author":"J Favier","year":"2012","unstructured":"Favier, J., Igaz, P., Burnichon, N., Amar, L., Libe, R., Badoual, C. et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr. Pathol. 23, 34\u201342 (2012).","journal-title":"Endocr. Pathol."},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/jc.2008-1836","volume":"94","author":"AM Joshua","year":"2009","unstructured":"Joshua, A. M., Ezzat, S., Asa, S. L., Evans, A., Broom, R., Freeman, M. et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma. J. Clin. Endocrinol. Metab. 94, 5\u20139 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1210\/jc.2008-1972","volume":"94","author":"C Jimenez","year":"2009","unstructured":"Jimenez, C., Cabanillas, M. E., Santarpia, L., Jonasch, E., Kyle, K. L., Lano, E. A. et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J. Clin. Endocrinol. Metab. 94, 386\u2013391 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"474_CR11","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez, M., Chougnet, C. N., Habra, M. A., Palmer, J. L., Leboulleux, S., Cabanillas, M. E. et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J. Clin. Endocrinol. Metab. 97, 4040\u20134050 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"474_CR12","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang, H., Abraham, J., Hung, E., Averbuch, S., Merino, M., Steinberg, S. M. et al. Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113, 2020\u20132028 (2008).","journal-title":"Cancer"},{"key":"474_CR13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/1097-0142(19951015)76:8<1476::AID-CNCR2820760827>3.0.CO;2-9","volume":"76","author":"SR Patel","year":"1995","unstructured":"Patel, S. R., Winchester, D. J., Benjamin, R. S. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 76, 1476\u20131480 (1995).","journal-title":"Cancer"},{"key":"474_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe, A., Naruse, M., Nomura, K., Tsuiki, M., Tsumagari, A., Ichihara, A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm. Cancer 4, 103\u2013110 (2013).","journal-title":"Horm. Cancer"},{"key":"474_CR15","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez, M., Feng, L., Habra, M. A., Rich, T., Dickson, P. V., Perrier, N. et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118, 2804\u20132812 (2012).","journal-title":"Cancer"},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer, N. D., Alblas, G., van Hulsteijn, L. T., Dekkers, O. M., Corssmit, E. P. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin. Endocrinol. 81, 642\u2013651 (2014).","journal-title":"Clin. Endocrinol."},{"key":"474_CR17","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux, J., Favier, J., Scoazec, J. Y., Leboulleux, S., Al Ghuzlan, A., Caramella, C. et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J. Cancer 135, 2711\u20132720 (2014).","journal-title":"Int J. Cancer"},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/modpathol.2013.233","volume":"27","author":"CA Cassol","year":"2014","unstructured":"Cassol, C. A., Winer, D., Liu, W., Guo, M., Ezzat, S., Asa, S. L. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod. Pathol. 27, 1050\u20131062 (2014).","journal-title":"Mod. Pathol."},{"key":"474_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming, T. R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 38, 143\u2013151 (1982).","journal-title":"Biometrics"},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","volume":"57","author":"S Jasim","year":"2017","unstructured":"Jasim, S., Suman, V. J., Jimenez, C., Harris, P., Sideras, K., Burton, J. K. et al. Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma. Endocrine 57, 220\u2013225 (2017).","journal-title":"Endocrine"},{"key":"474_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1803675","volume":"379","author":"A Mejean","year":"2018","unstructured":"Mejean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J. B., Bensalah, K. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. 379, 417\u2013427 (2018).","journal-title":"N. Engl. J. Med."},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1677\/erc.1.00838","volume":"11","author":"G Eisenhofer","year":"2004","unstructured":"Eisenhofer, G., Huynh, T. T., Pacak, K., Brouwers, F. M., Walther, M. M., Linehan, W. M. et al. Distinct gene expression profiles in norepinephrine and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr. Relat. Cancer 11, 897\u2013911 (2004).","journal-title":"Endocr. Relat. Cancer"},{"key":"474_CR23","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1210\/me.2010-0256","volume":"24","author":"E Lopez-Jimenez","year":"2010","unstructured":"Lopez-Jimenez, E., Gomez-Lopez, G., Leandro-Garcia, L. J., Munoz, I., Schiavi, F., Montero-Conde, C. et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol. Endocrinol. 24, 2382\u20132391 (2010).","journal-title":"Mol. Endocrinol."},{"key":"474_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","volume":"1","author":"PL Dahia","year":"2005","unstructured":"Dahia, P. L., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M. et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1, 72\u201380 (2005).","journal-title":"PLoS Genet."},{"key":"474_CR25","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604\u20134613 (1996).","journal-title":"Mol. Cell Biol."},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrclinonc.2010.42","volume":"7","author":"L Gossage","year":"2010","unstructured":"Gossage, L., Eisen, T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat. Rev. Clin. Oncol. 7, 277\u2013288 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"474_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","volume":"128","author":"R Roskoski Jr.","year":"2018","unstructured":"Roskoski, R. Jr., Sadeghi-Nejad, A. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharm. Res. 128, 1\u201317 (2018).","journal-title":"Pharm. Res."},{"key":"474_CR28","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias, S., Goldsby, R., Matthay, K. K., Hawkins, R., Price, D., Huberty, J. et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J. Clin. Oncol. 27, 4162\u20134168 (2009).","journal-title":"J. Clin. Oncol."},{"key":"474_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/cen.13434","volume":"87","author":"O Hamidi","year":"2017","unstructured":"Hamidi, O., Young, W. F. Jr., Gruber, L., Smestad, J., Yan, Q., Ponce, O. J. et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin. Endocrinol. 87, 440\u2013450 (2017).","journal-title":"Clin. Endocrinol."},{"key":"474_CR30","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin, E., Habra, M. A., Deschamps, F., Cote, G., Dumont, F., Cabanillas, M. et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur. J. Endocrinol. 171, R111\u2013R122 (2014).","journal-title":"Eur. J. Endocrinol."},{"key":"474_CR31","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders, J. W., Duh, Q. Y., Eisenhofer, G., Gimenez-Roqueplo, A. P., Grebe, S. K., Murad, M. H. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915\u20131942 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"474_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12022-012-9199-6","volume":"23","author":"S Nolting","year":"2012","unstructured":"Nolting, S., Grossman, A. B. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr. Pathol. 23, 21\u201333 (2012).","journal-title":"Endocr. Pathol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0474-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:55Z","timestamp":1684616695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0474-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0474-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"12 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the University Health Network (UHN) Research Ethics Board (REB) and submitted at each participating site. REB protocol number 08-0108. All patients provided informed consent as per study protocol. This consent included patient consent to collect clinical, demographic, genetic and outcome data for study publication. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"This study is available withinthis publication and in the supplementary material. Further patient data can be requested from the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}},{"value":"This study was funded as part of an Investigator Initiated Trial from Pfizer Canada. Dr Jennifer Knox, the Principal Investigator was the study sponsor.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}